Limits...
Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.

Li Y, Li Y, Li J, Pi G, Tan W - Onco Targets Ther (2014)

Bottom Line: Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors.A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports.Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.

ABSTRACT
Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.

No MeSH data available.


Related in: MedlinePlus

Visual field test.Note: Temporal hemianopsia and a nasal peripheral visual field defect were diagnosed during the right eye visual field study.Abbreviations: O/O, 0%; POS, positive; NEG, negative; SITA-fast, Swedish Interactive Threshold Algorithms; RX, correction of refractive errors; DS, Diopter sphere; DC, Diopter cylinder; GHT, Glaucoma Hemifield Test; VFI, visual field index; MD, mean defect; PSD, pattern standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4125372&req=5

f3-ott-7-1361: Visual field test.Note: Temporal hemianopsia and a nasal peripheral visual field defect were diagnosed during the right eye visual field study.Abbreviations: O/O, 0%; POS, positive; NEG, negative; SITA-fast, Swedish Interactive Threshold Algorithms; RX, correction of refractive errors; DS, Diopter sphere; DC, Diopter cylinder; GHT, Glaucoma Hemifield Test; VFI, visual field index; MD, mean defect; PSD, pattern standard deviation.

Mentions: Several ophthalmic examinations were performed after the patient became blind; the best-corrected visual acuities were 0.3 on the right and only slight light perception on the left. The intraocular pressures were normal bilaterally at 11 mmHg on the left and 13 mmHg on the right. The pattern visual-evoked potentials (VEPs) and transient, flash electroretinograms (ERGs) were abnormal (Figure 2A and C). Non-specific waves were found in his left eye (Figure 2A and C), but the VEP and ERG were normal in his right eye (Figure 2B and C). The direct ophthalmoscopic examination of the fundus, retina, and vitreous humor was normal bilaterally. The right eye had a normal visual field; the left eye visual field could not be assessed due to its loss of light perception (Figure 3). A temporal hemianopsia, and a nasal peripheral visual field defect were found in the right eye (Figure 3).


Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.

Li Y, Li Y, Li J, Pi G, Tan W - Onco Targets Ther (2014)

Visual field test.Note: Temporal hemianopsia and a nasal peripheral visual field defect were diagnosed during the right eye visual field study.Abbreviations: O/O, 0%; POS, positive; NEG, negative; SITA-fast, Swedish Interactive Threshold Algorithms; RX, correction of refractive errors; DS, Diopter sphere; DC, Diopter cylinder; GHT, Glaucoma Hemifield Test; VFI, visual field index; MD, mean defect; PSD, pattern standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4125372&req=5

f3-ott-7-1361: Visual field test.Note: Temporal hemianopsia and a nasal peripheral visual field defect were diagnosed during the right eye visual field study.Abbreviations: O/O, 0%; POS, positive; NEG, negative; SITA-fast, Swedish Interactive Threshold Algorithms; RX, correction of refractive errors; DS, Diopter sphere; DC, Diopter cylinder; GHT, Glaucoma Hemifield Test; VFI, visual field index; MD, mean defect; PSD, pattern standard deviation.
Mentions: Several ophthalmic examinations were performed after the patient became blind; the best-corrected visual acuities were 0.3 on the right and only slight light perception on the left. The intraocular pressures were normal bilaterally at 11 mmHg on the left and 13 mmHg on the right. The pattern visual-evoked potentials (VEPs) and transient, flash electroretinograms (ERGs) were abnormal (Figure 2A and C). Non-specific waves were found in his left eye (Figure 2A and C), but the VEP and ERG were normal in his right eye (Figure 2B and C). The direct ophthalmoscopic examination of the fundus, retina, and vitreous humor was normal bilaterally. The right eye had a normal visual field; the left eye visual field could not be assessed due to its loss of light perception (Figure 3). A temporal hemianopsia, and a nasal peripheral visual field defect were found in the right eye (Figure 3).

Bottom Line: Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors.A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports.Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Hubei Cancer Hospital, Wuhan, People's Republic of China.

ABSTRACT
Paclitaxel (PTX) and/or cisplatin (CDDP), as important cytotoxic anti-cancer agents, are widely used to treat various solid tumors. Both may cause moderate or severe neurotoxicity, but ocular neurotoxicity is also occasionally reported. A patient diagnosed with nasopharyngeal cancer suffering acute ocular neurotoxicity 10 days after paclitaxel and CDDP administration at the recommended dose is described in the present case report, and PTX- and/or CDDP-induced ocular neurotoxicity are summarized according to previous reports. Possible mechanisms and the potential diagnostic, therapeutic and predictive strategies of PTX- and/or CDDP-induced ocular neurotoxicity are reviewed, to help the oncologist to take the infrequent toxicity of cytotoxic drugs into account and improve patient safety during anti-cancer therapy.

No MeSH data available.


Related in: MedlinePlus